AccuStem Sciences, Inc. (ACUT)
OTCMKTS · Delayed Price · Currency is USD
0.2650
-0.0150 (-5.36%)
At close: Apr 9, 2026
AccuStem Sciences Employees
AccuStem Sciences had 2 employees as of December 31, 2024. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$806,905
Market Cap
4.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | -1 | -25.00% |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Vaccinex | 27 |
| Mosaic ImmunoEngineering | 8 |
| Bioxytran | 3 |
| Galera Therapeutics | 3 |
| Synlogic | 1 |
AccuStem Sciences News
- 3 months ago - AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) - GlobeNewsWire
- 7 months ago - AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning - GlobeNewsWire
- 7 months ago - AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th - GlobeNewsWire
- 10 months ago - AccuStem Sciences, Inc. Announces Chairman Purchase of Shares - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan - GlobeNewsWire
- 1 year ago - AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test - GlobeNewsWire